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In recent years increasing attention has focused on soluble fibrin complexes as
molecular markers for intravascular fibrin formation . These high molecular
weight soluble fibrin intermediates have been produced under a variety of
experimental conditions in vitro and in vivo (1-8) .
The demonstration of soluble fibrin complexes in the circulation of patients through assay
procedures, such as ethanol and protamine sulfate gelation, (9, 10) assays for cryofibrino-
gen (11), and more recently through agarose gel chromatography, (12, 13) has been
claimed to be of prime importance in the diagnosis of localized i atravascular thrombosis,
as well as disseminated intravascular coagulation. Indeed, the technique of agarose gel
chromatography for the detection of soluble fibrin complexes has been claimed by
Fletcher and co-workers (12) to afford a highly specific and sensitive means of detection of
subclinical leg vein thrombosis, a claim substantiated by the high degree of correlation
between abnormal agarose gel chromatograms and localized leg vein isotope accumulation
utilizing the '25I-labeled fibrinogen scanning technique. In spite of these preliminary
observations which delineate the diagnostic significance of soluble fibrin complexes,
information regarding the biological properties and the possible pathophysiological role of
these macromolecules is lacking.
In this communication we wish to report on a species of highly aggregated, high
molecular weight, soluble fibrin complexes which differ in regard to biophysical
characteristics from those originally described by Fletcher et al . (12) and which
possess significant biological properties. These complexes were first detected in
model systems in vitro; they were later produced in animal experiments; and
they were finally detected in a limited number of patients with a variety of
thrombotic disorders.
Reagents
Materials and Methods
Normal Plasma.
￿
Normal plasma was withdrawn from healthy male subjects (9 vol blood into 1
vol 3.8% trisodium citrate). The blood was immediately centrifuged at 7,000 rpm for 10 min;
* This investigation was presented in part at the 29th Annual Meeting of the American Federation
for Clinical Research, May, 1972, Atlantic City, N. J.
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supernatant plasma was used immediately or was immediately frozen and stored at -21°C. All
plasmas utilized in these studies were analyzed by agarose gel chromatography (see below) . A normal
chromatographic pattern, as defined in the following, was demonstrated for all plasmas, whether they
were used immediately or utilized after storage in the frozen state for different time periods.
Purified HumanFibrinogen.
￿
Purified human fibrinogen was prepared according to the methods
of Kazal et al. (14) and Mosesson and Sherry (15). The resultant preparations, 96-100% clottable,
were homogeneous by polyacrylamide get electrophoresis and agarose gel chromatography.
"5I-Labeled Fibrinogen. "61-labeled fibrinogen was prepared by the iodine monochloride
technique according to Izzo et al. (16) incorporating less than 0.5 atoms of iodine/molecule of protein .
The labeled fibrinogen preparation utilized in this series of experiments contained 97% clottable
radioiodine.
Antihuman Fibrinogen Antisera.
￿
Antihuman fibrinogen antisera were prepared in ourlaboratory
in goats and made monospecific through adsorption with normal human serum.
Thrombin.
￿
Thrombin was Parke-Davis topical thrombin (Parke, Davis & Co., Detroit, Mich.)
used without further purification.
Hirudin.
￿
Hirudin with a sp act of 3,800 U/ml protein was kindly supplied by Dr. Z. S. Latallo,
Department of Radiobiology, Institute of Nuclear Research, Warsaw, Poland.
Heparin. Heparin was sodium heparin (Eli Lilly & Co., Indianapolis, Ind.) containing 1,000
U.S.P. U/ml.
Techniques
Agarose Gel Chromatography. Chromatographic studies were performed using either 0.9 x
30-cm or 1.5 x 90-cm siliconized glass columns packed with Bio-Gel® A-5m (Bio-Rad Laboratories,
Richmond, Calif.), an agarose medium with an exclusion limit of 5,000,000 mol wt. In most
experiments the elution buffer was Tris, 0.06 M in 0.3 M NaCl, pH 7.6. In experiments focusing on
heparin resistance (see below) thebuffer used for calibration and elution wasbarbital, 0.0165 M in 0.3
M NaCI, pH 7.35. The flow rate varied between 8 and 9 cm'/h in small columns (0.9 x 30 cm) and
varied between 14 and 15 cm'/h in large columns (1.5 x 90 cm). In all instances flow rates were
adjusted through gravity feeding to rates sufficiently low to avoid compression of the agarose gel
medium. The volume of effluent delivered into individual fractions was determined by weighing all
test tubes before and after collection of the effluent. Void volumes of individual columns were
estimated with the use of platelet-rich plasma. Before determination of the void volume, columns
were re-equilibrated with a modified Tyrode's buffer containing no calcium chloride buttrisodium
citrate to afinal concentration of0.38%. Theeffluent volume of the first aliquot containing platelets,
as estimated by automated counting (Coulter Electronics Inc., Hialeah, Fla.), wastaken as the void
volume. Effluent fractions collected in experiments involving small columns (0.9 x 30 cm) measured
0.85 f 0.5 ml; effluent fractions collected in experiments involving large columns (1.5 x 90 cm)
measured 2.75 t 0.15 ml .
Four Methods of Determining the Content of Fibrinogen and Fibrinogen-Related Molecules in
Effluent Fractions. (a) Radial immunodiffusion modified from Mancini et al., (17). The diffusion
medium was 1% agarose containing 1% specific antifibrinogen antiserum and urea to 2 M. The
addition of urea to 2 M to the agarose facilitated diffusion of high molecular weight soluble fibrin
complexes and produced significantly greater zones of precipitation for these entities than were
observed in agarose without urea added. The presence of urea in the agarose medium did not
appreciably reduce theformation of precipitable antigen-antibody complexes. After 24 hincubation,
the plates were fixed with 1% tannic acid before measurements of the precipitin zones. (b) An
automated nephelometric immunoprecipitin assay (AIP) .1 The automated immunoprecipitation
assay was identical to the quantitative protein immunoassays performed by the Technicon
Immunoprecipitator (18) but utilized a manifold assembled in ourlaboratory from Technicon spare
parts and an Aminco nephelofluorimeter (American Instrument Co., Inc., Silver Springs, Md.)
equipped with a flow cell with a 3 mm light path. (c) A thrombin-clotting time technique modified
from Clauss (19). 0.2-ml aliquots from column fractions were admixed with 0.1 ml thrombin (200
'Abbreviations used in this paper: AIP, automated nephelometric immunoprecipitin assay; FDP,
fibrinogen degradation products; 111,0, immunoreactive fibrinogen ; RID, radial immunodiffusion;
SFC, soluble fibrin complex(s); TCT, thrombin-clotting time(s).946
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U/ml in saline) and the clotting time recorded with the help of a Fibrometer (Baltimore Biological
Laboratories, Cockeysville, Md.) . In the presence of these high quantities of thrombin, the clotting
times depend largely on substrate concentration and are relatively insensitive to the presence of
fibrinogen-fibrin degradation products. (d) A clottable protein assay, according to Ratnoff and
Menzie (20), was utilized in some experiments; to provide sufficient fibrinogen, 2.0-ml aliquots of
effluent fractions were clotted.
Preparation of High Molecular Weight Soluble Fibrin Complexes In Vitro (Thrombin-Treated
Plasma). Platelet-poor plasma was incubated with 0.04 Uof thrombin/ml at room temperature for 5
min (method I). Residual thrombin activity was blocked with hirudin, added to a final
concentration of 0.4 U/ml plasma. The ethanol gelation test (9), a rapid test to demonstrate soluble
fibrin complexes, was strongly positive for all plasmas prepared in this fashion.
To provide sufficient material to allow for clottable protein analysis of soluble fibrin complexes,
platelet-poor plasma wastreated more extensively with thrombin (method II). Platelet-poor plasma
was incubated with 0.08 U of thrombin/ml at room temperature for 15 min. Residual thrombin
activity was blocked with hirudin added to afinal concentration of 1 U/ml of plasma. Thesmall clots,
which occasionally formed during incubation of these mixtures, were removed before chromatogra-
phy.
In experiments involving the use of purified fibrinogen as the starting material for soluble fibrin
complexes, fibrinogen (5 mg/ml) in 0.06 M Tris, 0.3 M saline, pH 7.6, was incubated with thrombin
(0.02 U/ml) at room temperature for 5 min. Residual thrombin activity was again blocked with
hirudin added to a final concentration of 0.2 U/ml incubation mixture. 1 ml of these incubation
mixtures was separated by Bio-Gel chromatography on small columns (0.9 x 30 cm); 5 ml of these
incubation mixtures wereutilized in experiments using large columns (1.5 x 90 cm).
Thrombin Sensitivity.
￿
Appropriate dilutions were prepared from selected effluent fractions using
0.06 M Tris, 0.3 M saline, pH 7.6, as a diluent. Aliquots (0.2 ml) of undiluted and diluted effluent
fractions were admixed with 0.1 ml of thrombin (200 U/ml in saline) and the clotting times of the
mixtures recorded.
In additional experiments, 0.2-ml aliquots ofundiluted effluent fractions were admixedwith 0.1 ml
of thrombin in saline containing 0.1, 0 .2, 0.3, 0.4, and0.5 U. All clotting times were recorded with the
aid of the Fibrometer.
The influence of effluent fractions on the thrombin-clotting time of normal plasma wasassayed in
the following manner. Normal plasma, 0.1 ml, was admixed with 0.2 ml of appropriate column
fractions. The mixture was clotted with 0.1 ml thrombin (20 U/ml). Clotting times were recorded in
the Fibrometer. The control consisted of 0.1 ml normal plasma and0.2 ml column buffer (Tris, 0.06
M, 0.3 M NaCl, pH 7.6) clotted with 0.1 ml thrombin (20 U/ml) .
Heparin-sensitized Thrombin-Clotting Time Assay.
￿
Assay conditions are specified in Fig. 9.
In Vivo Experiments.
￿
Male or female albino rabbits (1.5-2 kg) were utilized. All rabbits received
50 Uofthrombin dissolved in 10 ml of normal saline through slow intravenous infusion in the ear vein
over a period of exactly 5 min. At 1, 2, 4, 6, 8, 10, 20, and 30 min after thetermination of thrombin
administration, blood samples were withdrawn by heart puncture for analysis for soluble fibrin
complex content by agarose gel chromatography.
Patient Studies.
￿
Patients included in these studies were admitted to Indiana University School
of Medicine hospitals. Two groups of patients were evaluated.
The first group included 12 patients, all admitted with a clear-cut diagnosis of major
thromboembolic disease. Nine of these patients presented with unequivocal clinical evidence of a
recent onset of extensive deep-vein thrombosis . In five of these nine patients there was also strong
evidence of pulmonary embolism by clinical criteria, blood gases, and lung scans. Three additional
patients in this group presented with a picture of major completed thrombotic cerebrovascular
accidents . Blood samples with withdrawn from all patients within 24 h after their admission. In no
instance were the patients on anticoagulant drugs at the time of blood sampling.
The second group encompassed 20 patients undergoing major surgery. 13 patients underwent
major abdominal surgery ; 2 patients had radical mastectomies ; and 5 patients underwent thoracic
surgery (lobectomies or pneumonectomies) . 13 of these 20 patients underwent surgery for malignant
disease. Blood samples were obtained between 12 and48 h after surgery in all instances . Platelet-poor
plasma wasprepared, as outlined above. Plasmas were either analyzed immediately by fibrinogen gelchromatography or were immediately frozen, stored at -21°C, and analyzed later . Agarose gel
chromatography was performed on small columns for all patients' samples .
Results
The chromatographic behavior of normal plasma applied to a large column of
Bio-Gel A-5m is demonstrated in Fig . 1 . 5 cm' of normal plasma was applied to
this column calibrated at a void volume of 47 cml, and fibrinogen can be seen to
elute in a sharply defined symmetrical peak around an effluent volume of 72 cm I .
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Bio-Gel® A-5m chromatography of normal plasma (large column). Effluent fractions
assayed for fibrinogen by RID, AIP, and TCT.
Fig . 1 illustrates the comparison of three assays for quantifying fibrinogen in the
effluent : radial immunodiffusion (RID), the AIP assay, and the thrombin-clot-
ting time (TCT) assay . It can be seen that the two immunoassays show excellent
agreement and also that the thrombin-clotting times performed on individual
fractions closely parallel the fibrinogen values obtained by the two immunoas-
says .
In the experiment depicted in Fig. 2, 5 ml of thrombin-treated plasma,
prepared according to method I, was subjected to Bio-Gel chromatography . The
tracing designated IRO (immunoreactive fibrinogen) in this and the following
figures represents the average values for the two immunoassays . The tracing
designated TCT represents the thrombin-clotting times . It can be seen that the948
￿
SOLUBLE FIBRIN COMPLEXES
w
w
H
C7
z
F
F
d
A
ty
i
z
x
40 50 60 70 80 90
ELUTION VOLUME (ml)
FiG. 2 .
￿
Bio-Gelo A-5m chromatography ofthrombin-treated plasma (large column) . Tracing
designated IRO represents average values of RID and AIP . Tracing designated TCTrepresents
thrombin clotting time .
TCT pattern shows a distinct two-peak pattern with an early peak appearing
close to the void volume of this column in an area of effluent were only trace
quantities of fibrinogen are detectable by immunoassays . Based on the chro-
matographic behavior of fibrinogen and a variety of fibrinogen derivatives,
previously published from our laboratory (21), we estimated the mol wt of this
early-peak material to be in excess of 1 million .
Similar differences could be demonstrated by agarose gel chromatography on
smaller columns calibrated at a void volume of 6.4 ml, the type of column
originally suggested by Fletcher and co-workers for diagnostic purposes (12, 13) .
As seen in the upper graph depicted in Fig . 3, elution patterns for IRO andTCT
were in close agreement for normal plasma applied to this column in a volume of
1 cm ,; whereas, the TCT for thrombin-treated plasma (method I) applied to the
column in a 1-cm' vol, as displayed in the lower graph, showed a distinct
two-peak pattern with the early peak eluting close to the void volume where only
traces of IRO were demonstrable .
Gel chromatography of 25 mg of thrombin-treated highly purified fibrinogen
applied to a large column at a 5-cm' vol again produced fibrin complexes in the
effluent region close to the void volume demonstrable by TCT assays (Fig . 4) .
Under these circumstances, one could also detect an early peak ofIRO exhibiting
an elution peak a few milliliters later than the TCT peak .m
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FIG. 3 . Bio-Gel® A-5m chromatography of normal and thrombin-treated plasma (small
column) .
To exclude methodological artifacts as the reason for low values of fibrinogen
obtained in effluent regions in which a shortening of the TCT was noted, we
conducted additional experiments . Depicted in Fig. 5 is an experiment in which
'261-labeled fibrinogen was added to normal plasma before treatment with
thrombin, according to method 1 .
As can be seen, the material contained in the early effluent peak in this
experiment incorporated only 6% of the total radioactivity present in the
thrombin-treated plasma subjected to Bio-Gel chromatography . This confirms
the impression that the highly aggregated soluble fibrin complexes (SFC)
demonstrable by theTCT technique contain only small quantities of fibrinogen .
In three experiments (Table 1) the fibrinogen content from fractions exhibiting
the shortest TCT in the SFC and native fibrinogen effluent regions was
quantified as clottable protein, as well as by immunoassays . The plasmas utilized
in these experiments were treated more extensively with thrombin according to
method II providing sufficient material to allowfor accurate clottable protein esti-950
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FIG. 4. Bio-Gel© A-5m chromatography of thrombin-treated purified fibrinogen (large
column).
mates in SFC fractions. There is a good agreement between fibrinogen values by
clottable protein assays and by immunoassays inboth the SFC and native fibrino-
gen peak fractions. Although SFC peak fractions by either assay contain consid-
erably less protein than native fibrinogen peak fractions, TCT of soluble com-
plex fractions are always shorter than in native fibrinogen fractions.
To account for these results, one couldspeculate that SFC are moresensitiveto
thrombin action than regular fibrinogen. A comparison of TCT of several
dilutions of fractions containing SFC and dilutions of native fibrinogen sup-
ported this concept (Fig. 6). Appropriate dilutions of purified fibrinogen and
SFC, separated from thrombin-treated fibrinogen by agarose gel chromatogra-
phy, were clotted with thrombin.
A linear relationship between fibrinogen concentration and TCT was obtained
for native fibrinogen between 2,880 and 720 Ag/ml. Below 720 jug/ml the
relationship was no longer linear, and at concentrations of280wg/ml orless, TCT
were infinitely long. In contrast, 280,ug/ml ofa SFC fraction exhibited a TCT of
24 s. There was a linear relationship between protein concentration and TCT for
SFC fractions between 280 and 95 mg/ml; at the latter protein concentration, a
TCT of 62.5 s was recorded. At protein concentrations of 70 ,ug/ml and below,
TCT for SFC fractions went to infinity.
Further support for the hypothesis of enhanced thrombin sensitivity of SFC
was obtained in experiments in which the substrate concentrations were keptM . S . HANSEN, N . U . BANG, R . D . BARTON, AND L . E . MATTLER
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FIG . 5 . Bio-Gelm A-5m chromatography of thrombin-treated normal plasma .
human fibrinogen was added before thrombin treatment. Effluent fractions
radioactivity and TCT (large column) .
TABLE I
Fibrinogen Determined by a Clottable Protein Assay, Immunoassays, and TCTfor SFC
Fractions and Main-peak Fibrinogen Fractions
120
12'I-labeled
assayed for
951
constant but enzyme concentrations were varied (Fig . 7) . Clotting times at
differentthrombin concentrations for main-peak fibrinogen andtheSFC fraction
were compared . The starting material in this experiment was 5 ml of plasma
treated with thrombin, according to method I, and subjected to Bio-Gel
chromatography .
As can be seen from Fig . 7, the early-peak material clotted significantly more
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TCT as a function of protein concentration in native fibrinogen solutions and SFC
fractions. Aliquots (0.2 ml) of fibrinogen or SFC fractions contained in 0.06 M Tris, 0.3 M
saline, pH 7 .6, were diluted with the same buffer and admixed with 0.1 ml of thrombin (200
U/ml in saline). Clotting times at 37°C were recorded on the fibrometer.
rapidly at this range of thrombin concentrations (0.1-0.5 U/ml) than did the
main-peak fibrinogen, although the concentration of IRO of the SFC utilized in
this experiment was only one-fourth of the concentration of IRO from the
main-peak material.
Similar results to those depicted in Fig. 7 were obtained in three additional
experiments using thrombin-treated plasma as a starting materialto producethe
soluble complexes and in an additional three experiments in which purified
fibrinogen treated with thrombin was separated by agarose gel chromatography
to prepare soluble complexes.
SFC fractions usually produce visible gels upon lowering the temperature or
upon lowering the ionic strength through dialysis against distilled water. For this
reason we examined the possibility that the enhanced rate of coagulation
observed for SFC fractions reflects discreet changes in the ionic milieu of the
sample, rather than the addition of thrombin. Discreet, but significant, lowering
of the ionic strength of the sample is introduced in our standard thrombin-clot-
ting assay (0.2 ml of sample fraction in 0.06 M Tris, 0.3 M NaCl, pH 7.6 is
"diluted" with 0.1 ml of thrombin in 0.15 M NaCl). This possibility was
excluded, since we observed that the dilution of two volumes of soluble fibrin
complex fractions with one vol of 0.15 M saline did not produce spontaneous
gelation ofthe sample over a 24 h period ofobservation at 37°C. Furthermore, the
clotting times obtained for SFC fractions were identical, irrespective of whether
the thrombin used in the assay was dissolved in 0.15 Msaline or whether it was
dissolved in 0.06 M Tris, 0.3 M saline, pH 7.6. The pH optimum forthe reaction
lied between 7.6 and 8.0; a change of the pH to 8.5 or to 6.0 produced
considerably longer clotting times than was observed at pH 7.6. It would,
therefore, appear that the "abnormally short" TCT observed for SFC fractions
are unlikely to be caused by nonspecific ionic strength and pH effects.
Fig. 8 depictsthe results ofeight experiments aimed at comparingthe effects of
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FIG. 7 . Clotting times of fractions from early SFC peak and major fibrinogen peak at
different thrombin concentrations . Starting material was thrombin-treated normal plasma .
Fractions were separated on a large Bio-Gel® A-5m column . PR, per .
soluble fibrin complexes and fibrinogen from the main peak on the TCT of
normal plasma . In four experiments soluble complexes and fibrinogen were
harvested from agarose gel chromatography of thrombin-treated plasma (method
I), and in four experiments thrombin-treated purified fibrinogen was used as the
starting material . Under the assay conditions employed, it can be seen that
main-peak fibrinogen produced little or no shortening of theTCT ; whereas, SFC
from the early peak, even at very low concentrations, produced a substantial
shortening of theTCT of normal plasma, as illustrated by the lowest bar in Fig. 7.
The addition of highly aggregated soluble complexes to normal plasma also
produced a decrease in heparin sensitivity, as illustrated by the heparin-sensi-
tized thrombin-clotting assay (Fig. 9) . The data presented here again includes
eight experiments, four utilizing thrombin-treated plasma and four utilizing
thrombin-treated purified fibrinogen for the preparation of SFC . The top bar in
Fig. 9 represents the mean normal plasma TCT without heparin in the system . It
can be seen from the lowest bar in the diagram that the normal plasma TCT in
the presence of SFC is prolonged only insignificantly by the addition of a954
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The effect on theTCT of normal plasma offractions from the earlySFC peak and the
major fibrinogen peak . The figure summarizes eight experiments, four employing normal
thrombin-treated plasma and four employing thrombin-treated fibrinogen as the starting
material for the preparation ofSFC . The fractions were separated on a large Bio-Gel© A-5m
column .
standard amount of heparin in comparison to the substantial prolongation in the
controls in which either main-peak fibrinogen or buffer was admixedwith normal
plasma before the addition of an identical amount of heparin (the two middle
bars) .
To assess the pathological implications of these findings, it seemed critical to
demonstrate the presence of biologically active SFC in vivo . In the experiment
shown in Fig . 10, a plasma sample was obtained from a rabbit 1 min after the
administration of 50 U of thrombin, intravenously, and subjected to Bio-Gel
chromatography . As can be seen from Fig . 10, the TCT of effluent fractions
showed a broad distribution representing a wide range of different molecular
weight soluble complexes with significant amounts of material eluting close to
the void volume in an effluent zone where once again only trace quantities ofIRO
were demonstrable .
In additional studies in rabbits we obtained data to indicate that this
early-peak material is short-lived . In timed studies we were able to demonstrate
thrombin-sensitive SFC with abroad molecular weight distribution in decreasing
quantities at 1, 2, 4, 6, 8, and 10 min after the infusion of 50Uofthrombin . At 20
and 30 min after the thrombin infusion the fibrinogen gel chromatograms had
resumed their normal symmetrical shape .
Fig . 11 illustrates an agarose gel elution pattern for plasma fibrinogen in a
patient who presented at Marion County General Hospital with the unquestiona-
ble clinical diagnosis of multiple pulmonary emboli . A characteristic two-peak
pattern according to theTCT assay emerged with a large early peak of SFC not
demonstrable by immunoassays . Our clinical experience so far encompasses 12
patients with well-documented thromboembolic disease ; and this thrombin-sen-
sitive highly aggregated polymeric material was demonstrated in 3 patients in
this group . In addition, we examined 20 patients within 48 h after majorSYSTEM
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The effect ofa heparin-sensitized TCT assay of fractions from the early SFC peak and
major fibrinogen peak. The figure summarizes eight experiments, four in which normal
thrombin-treated plasma and four in which normal thrombin-treated purified fibrinogen was
utilized for the preparation of SFC . Fractions were separated on a large Bio-Gel® A-5m
column .
abdominal or thoracic surgery but could demonstrate thrombin-sensitive poly-
meric material in only two of these patients, an incidence substantially lower
than the incidence of gel chromatographic abnormalities, previously noted by
Fletcher et al . (12), in patients undergoing surgery (25 abnormal chromatograms
among 91 assays on 55 patients) .
Discussion
Our studies demonstrated an unexpected property of SFC, an ability to enhance
the rate of normal fibrinogen-to-fibrin conversion . This curious characteristic
was first suspected in experiments in which significant discrepancies arose
between fibrinogen estimates by immunochemical techniques and fibrinogen
estimates by a TCT technique performed in the presence of excess thrombin . We
observed that polymeric fractions of high molecularweight exhibited short TCT,
although the estimated content of fibrinogen in these fractions was low by
immunochemical assays .
Several possibilities were considered to explain these discrepancies . The
immunological techniques utilized in these studies for the quantification of956
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FIG. 10 . Bio-Gel© A-5m chromatography of rabbit plasma withdrawn 1 min after the
completion of infusion of 50 U of thrombin, intravenously (large column) .
fibrinogen could conceivably underestimate the true fibrinogen content in
polymeric fractions because of the limited capability of these macromolecules for
diffusion in gel media. However, we considered this unlikely ; since the results of
the immunodiffusion assays for fibrinogen incorporating urea to 2 M in the
agarose medium closely agreed with the results obtained through a nephelomet-
ric immunoprecipitation assay, the latter assay being independent of the
diffusion constant of the antigenic material .
IRO could be underestimated if antigenic sites of the fibrinogen molecule were
obscured through conformational changes arising during intermediate polymer
formation . We considered this possibility unlikely in view of our experiments in
which the distribution of radiolabeled fibrinogen between higher and lower
molecular weight fractions paralleled the distribution of fibrinogen and SFC
estimated by the two types of immunochemical assays .
Moreover, in additional experimentswe observed that thevalues for fibrinogen
estimated by a clottable protein assay, closely paralleled the lower values
observed by immunochemical assays in SFC fractions, as well as the higher
values obtained through immunoassays on "main-peak" fibrinogen fractions .
We next considered the possibility that the discrepancies between levels of
immunoassayable fibrinogen andTCT estimates of fibrinogen in soluble polymer
fractions could reflect enhanced thrombin sensitivity of higher molecular weightM . S . HANSEN, N . U . BANG, R . D . BARTON, AND L . E . MATTLER
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Bio-Gel® A-5m chromatography of plasma from a patient with documented multiple
pulmonary emboli (small column) .
SFC.We confirmed this hypothesis in experiments in which substrate concentra-
tions were varied at constant enzyme concentrations and experiments in which
enzyme concentrations were varied in the face of constant substrate concentra-
tions. In both instances, clotting times utilized over the range of substrate and
enzyme concentrations were significantly shorter for SFC than for native
fibrinogen . Nonspecific effects arising from a change in the ionic environment of
the SFC, as a consequence of the test procedure, were excluded ; since it was es-
tablished that TCT were identical, irrespective of whether the thrombin added
was dissolved in 0.15M saline (the standard test procedure) or was dissolved in
the standard column buffer (0.06M Tris, 0.3M saline, pH 7.6) .
We also observed that the soluble complex fractions in small quantities appre-
ciably enhanced the gelation rate ofnormal fibrinogen, as evidenced by a shorten-
ing of the TCT or a heparin-sensitized TCT of normal plasma . The biochemical
basis for these findings is obscure . In experiments involving plasma treated with
thrombin, fractions containing SFC also contained significant quantities of anti-
hemophilic globulin and alpha, macroglobulin, in addition to varying amounts of
low-density beta lipoproteins . The possibility that these proteins in some way
accelerate the thrombin-catalyzed fibrinogen-to-fibrin conversion can largely be
excluded, since experiments utilized highly purified fibrinogen containing no de-
tectable beta lipoproteins and only trace quantities of antihemophilic globulin958
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gave essentially the same results, as did experiments in which normal plasma
was used as a starting material to produce soluble complexes. Nevertheless, one
cannot exclude the possibility of participation of nonfibrinogen proteins in solu-
ble complex formation . Indeed, we have recently obtained preliminary evidence
suggesting that cold insoluble globulin incorporates to a significant degree into
SFC in thrombin-treated plasma (22) . However, the functional significance of this
observation remains obscure .
Soluble fibrin macromolecules react with thrombin, implying that these
polymers retain some thrombin-sensitive sites, i.e . soluble polymers must
contain monomeric units still possessingA orB peptides ; but it remains obscure
why such soluble aggregates even at very low concentrations are capable of an
enhanced rate of gelation upon incubation with thrombin . Similarly, the ability
of soluble complex fractions to shorten the TCT of normal plasma or fibrinogen
and to render normal plasma heparin resistant cannot be explained at the
present time on the basis of enzyme kinetics . Soluble fibrin complexes could
conceivably enhance normal fibrin gelation, as they may constitute a nidus
around which enhanced polymerization could occur .
Our demonstration of highly aggregated SFC in the plasma of rabbits after
thrombin infusions confirmed earlier observations reported by Lee (23) and Lee
and McCluskey (24) . These authors first pointed out that intravenous injections
of endotoxin or the slow intravenous infusion of thrombin does not result in
massive disposition of fibrin in tissues but rather converts circulating fibrinogen
into soluble fibrin aggregates ("heparin-precipitable fibrinogen"), which are
subsequently rapidly removed by the reticuloendothelial system in the liver and
in the spleen . The demonstration of similar, highly aggregated, thrombin-sensi-
tive SFC in occasional patients suggests a pathophysiological role for these
aggregates in thrombotic states in man . In a subsequent clinical series to be
reported elsewhere2 and which focuses on postoperative patients with phlebo-
graphically documented deep-vein thrombosis, we have not again encountered
these highly aggregated, thrombin-sensitive complexes in one single instance .
The chromatographic abnormality encountered in these patients with considera-
ble frequency is an early shoulder on the fibrinogen peak in an estimated mol wt
range of 500,000-700,000 consistent with a smaller aggregate, presumably a
dimer .
Recently, Alkjaersig et al . (25) applying computer analysis to fibrinogen gel
chromatograms, obtained from patients with thrombotic states, have postulated
the existence of two species of fibrinogen-fibrin complexes possessing minimum
mol wt of 430,000 and 550,000 but apparently have not detected the highly
aggregated complexes of higher molecular weight described in this communica-
tion . In extensive in vitro studies in our laboratory, we have been unable to
produce aggregates in the dimeric size range through the addition ofthrombin to
plasma or fibrinogen using a wide range of concentrations of enzyme and
substrate . Similarly, we have been unable to produce such aggregates by
incubating mixtures of fibrinogen and a variety of plasmic fibrinogen degrada-
2 Hansen, M. S., T. Kim, E. T. Yin, N. U. Bang, and J. Glover . Comparison of different in vitro
and in vivo approaches toward detection of subclinical thrombosis. Manuscript in preparation.M . S . HANSEN, N. U. BANG, R. D . BARTON, ANDL. E. MATTLER
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tion products (FDP) with thrombin (21, 26) . Under these circumstances, the
aggregates which formed are of the same type as the aggregates described in this
publication possessing apparent mol wt somewhere in excess of 1 million . Recent
work in our laboratory (27, 28), as well as a preliminary report by Alkjaersig and
Fletcher (29), suggests that the complexes in the dimeric size range can occur as a
consequence of aggregation between higher molecular weight degradation prod-
ucts of noncross-linked fibrin and unaltered fibrinogen . This reaction may occur
in the absence of thrombin . Thus, thefibrinogen gel chromatographic abnormali-
ties, which have been frequently observed in clinical situations by Fletcher et al .
(12, 13) and by ourselves , 2 could be the direct consequence of fibrinolysis rather
than ongoing generation and fibrin deposition . However, this hypothesis assumes
that part of the fibrin in intravascular thrombotic deposits remains noncross-
linked, an assumption which awaits experimental verification . The highly
aggregated, thrombin-sensitive polymers which we have observed in only a few
patients may reflect ongoing thrombin generation and fibrin deposition .
Our rabbit experiments showing that such aggregates are cleared rapidly and
effectively from the circulation, presumably by the reticuloendothelial system,
provide a reasonable explanation why this type of polymer is only infrequently
observed in clinical thrombotic states . Thus, this particular type of thrombin-
sensitive fibrin complexes is probably too short-lived in the circulation to be of
practical diagnostic significance, in contrast to smaller aggregates in the dimeric
size range . It is conceivable, however, that these particular species of high
molecular weight thrombin-sensitive SFC may have a significant pathophysio-
logical role in the short time span during which they circulate . Since these
macromolecules are capable of enhancing the rate ofbloodcoagulation, they may
contribute to a temporary "hypercoagulable state" and may accelerate the
buildup and extension of thrombotic deposits .
Summary
We have detected aspecies of soluble fibrin complexes with significant biological
properties . Agarose gel chromatography of normal plasma or purified fibrinogen
previously incubated with small amounts of thrombin revealed the presence ofa
species of high molecular weight soluble fibrin complexes, which contained only
small quantities of fibrinogen by immunological assays but which exhibited
enhanced sensitivity to thrombin . In addition, these complexes substantially
shortened the thrombin-clotting time of normal plasma and enhanced the
resistance of normal plasma to heparin action . Similar thrombin-sensitive
soluble fibrin complexes were demonstrated in vivo in rabbits for up to 10 min
after the infusion of 50 U of thrombin . Thrombin-sensitive soluble fibrin
complexes were also demonstrated in 3 of 12 patients with documented
thromboembolic disease and in 2 of 20 patients after major surgery. High
molecular weight soluble fibrin complexes, which exhibit enhanced thrombin
sensitivity and which are capable of increasing the rate of normal fibrinogen-to-
fibrin conversion bythrombin, may appear consequent to clinical thrombosis and
situations involving trauma (e.g ., major surgery) . Such soluble complexes,
although they have no proven role in the primary pathogenesis of intravascular960
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thrombosis, may contribute to a temporary "hypercoagulable state" and may
accelerate the build-up and extension o£ already existing thrombotic deposits .
Received for publication 8 July 1974 .
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